Raising Health
Supercharging Discovery with Evan Feinberg
Oct 31, 2023
Evan Feinberg, founder and CEO at Genesis Therapeutics, talks about using AI in drug discovery and the collaboration between ML, biotech, and chemistry. They discuss how physics-based models can improve drug design, integrating human intuition and predictive AI models, and the importance of a multidisciplinary team in drug discovery programs.
29:07
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Genesis Therapeutics uses AI to tackle drug discovery through their interdisciplinary approach, combining chemists, software engineers, and machine learning researchers to develop their internal platform called Nucleus.
- AI in drug discovery requires a combination of human expertise and machine learning algorithms specifically tailored to the complex world of drug design, as the field necessitates extrapolation and the ability to discover new chemical matter.
Deep dives
Genesis Therapeutics: Tackling Drug Discovery through AI
Evan Feinberg, founder and CEO of Genesis Therapeutics, discusses how his work in the lab led to the creation of Genesis, which uses AI to tackle the problem of drug discovery. The company takes an interdisciplinary approach, combining the expertise of chemists, software engineers, and machine learning researchers to develop their internal platform called Nucleus. This platform allows chemists to access the latest ML models for predicting various properties, enhancing productivity and providing human feedback. Feinberg emphasizes the importance of unifying biotech with AI to fundamentally change the drug discovery process.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
